Assessment of Non-Alcoholic Fatty Liver Disease in Type 2 Diabetic Patients From South of Libya
Article Sidebar
-
Diabetes Mellitus, Fatty Liver, Libya, NAFLD, Ultrasonography
Abstract
Non-alcoholic fatty liver disease (NAFLD) is emerging as one of the most common chronic liver diseases worldwide; however, no published work has been found about its prevalence among Libyan diabetics or the general population. The present study aimed to determine the magnitude of NAFLD among type 2 diabetic patients (DM) from south of Libya. Eighty-five (85) Type 2 diabetic patients (35 males & 50 females) attending Traghen Hospital (south of Libya) were utilized in this cross-sectional study. All the participants were examined for the presence of fatty liver via ultrasonography. Biochemical parameters (fasting blood sugar, total cholesterol, triacylglycerol, alanine aminotransferase, and aspartate aminotransferase) were also measured. Ultrasonography examination showed that 40% of Type 2 DM patients included in this study had non-alcoholic fatty liver disease, of whom 56%, 38%, and 6% had mild, moderate, and severe grade fatty liver, respectively. Serum triacylglycerol and fasting blood sugar were significantly higher (P = 0.007, 0.043, respectively) in type 2 DM patients with NAFLD compared with those without NAFLD; however, other biochemical parameters showed no significant differences (P˃0.05). The distribution of NAFLD among Type 2 DM patients was significantly associated with duration of diabetes condition and serum level of triacylglycerol (P = 0.018 and 0.033, respectively). We conclude that diabetic patients with hypertriglyceridemia, especially those with long durations of diabetes, are highly advised to undergo ultrasonography examinations for early detection of fatty liver disease.
Full text article
References
[1]-Ratziu V., Bellentani S., Cortez-Pinto H., Day C., Marchesini G., (2010): "A position statements on NAFLD/ NASH based on the EASL 2009 special conference". J Hep., 53(2): 372-384.
[2]-Younossi Z., Gramlich T., Matteoni C., Boparai N., et al., (2004): " Non-alcoholic fatty liver disease in patients with type 2 diabetes". Cli Gastro Hep., 2(3): 262-265.
[3]-Targher G., Day C., Bonora E., (2010): "Risk of cardiovascular disease in patients with Non-alcoholic fatty liver disease". New Eng J Med., 363(14): 1341-50.
[4]-Daboul M., (2010). " A study of ALT elevation in association with triglycerides, cholesterol and glucose elevation in human serum". J Arab Board H Spec., 11(2): 64-70.
[5]-Kikuchi L., Oliveira C., Carrilho F., (2014): "Nonalcoholic fatty liver disease and hepatocellular carcinoma". Bio Med Res Int.,Http://dx.doi.org/10.1155/2014/106247.
[6]-Dobhi A., Brahmbhatt K., Pandya T., (2008): " Non-Alcoholic fatty liver disease". JIACM., 9(1): 36-41.
[7]-Qian Y., Fan J., (2005): "Obesity, fatty liver and liver cancer". Hep Pan Dis Int., 4(2): 173-177.
[8]-Qari F., Al-Ghamdi A., (2005): "Fatty liver in overweight and obese patients in western part of Saudi Arabia". J Bah Med Soc., 17(2): 95-99.
[9]-Obika M., Noguchi H., (2012): "Diagnosis and evaluation of Nonalcoholic fatty liver disease". Exp Dia Res., http://dx.doi:10.1155/2012/145754.
[10]-Cohen j., Horton J., Hobbs H., (2011): "Human fatty liver disease; old questions and new insights". Science 332(6037): 1519-23. doi:10.1126/science.1204265.
[11]-Agrawai S., Bonkovsky H., (2002): "Manegment of Nonalcoholic steatohepatitis". J Cli Gastr., 35: 253-261.
[12]-Akha O., Fakheri H., Abadi R., MahdaviM., (2010): "Evaluation of the correlation between Non-alcoholic fatty liver disease and insulin resistance". I Red Cre Med J., 12(3): 282-286.
[13]-Birjandi M., Ayatollahi S., Pourahmad S., Safarpour A., (2016): "Prediction and diagnosis of Non-alcoholic fatty liver disease (NAFLD) and identification of its associated factors using the classification tree method". I Red Cre Med J., 18(11): e32858. doi: 10.5812/ircmj.32858.
[14]-Khammas A., Mohammed S., Abu-Hassan H., Shahar H., et al., (2018): "Factors associated with nonalcoholic fatty liver disease grades detected by ultrasound at a screening center in Klang Valley, Malaysia". J Fac Med Bagh., 60(1): 32-37.
[15]-Saki F., Karamizadeh Z., (2014): " Metabolic syndrome, insulin resisitence and fatty liver in obese Iranian children". I Red Cre Med J., 16(5): e6656. diol:10.5812/ircmj.6656.
[16]-Angulo P., (2002): " Medical progress: non-alcoholic fatty liver disease". N Eng J Med., 346(16): 1221-31.
[17]-Tavakolit T., Kazemi T., Mollaei H., Salmani F., et al., (2018): " The relationship between the prevalence of Non-alcoholic fatty liver disease(NAFLD) with severity of coronary artery disease (CAD) in patients undergoing coronary artery angiography; A cross-sectional study". I Red Cre. Med J., 20(6): e58369. dio:10.5812/ircmj.58369.
[18]-Borai I., Shaker Y., Kamal M., Ezzat W., et al., (2018): "Association of nonalcoholic fatty liver disease grades with the plasma cell antigen-1 (PC-1) gen polymorphism". E J Med H Gen., 19: 241-246.
[19]-Albayati S., Sabbar R., (2018): "Prevalence of Nonalcoholic fatty liver disease in type 2 diabetic Iraqi patients". J Arab Boa Hea Special., 19(1): 11-18.
[20]-Mekawy A., Ahmed H., Mohamed W., Yehia Y., (2015): "Association of insulin resistance with alanine aminotransferase activity in patients with Non-alcoholic fatty liver disease". Assiut Med J., 39(2): 63-70.
[21]-Kotronen A., Yki-Jarvinen H.,(2008): " Fatty liver A novel component of the metabolic syndrome". Artr Throm Vasc Biol., 28: 27-38.
[22]-Pate N., Peterson M., Lin G., Feldstein A., et al., (2013): "Insulin resistance increases MRI-estimated pancreatic fat in Nonalcoholic fatty liver disease and normal controls". Gastr Res Prac., doi.org/10.1155/2013/498296.
[23]-Mazza A., Fruci B., Garinis G., Giuliano S., et al., (2012): "The role of metformin in the management of NAFLD". Exp Diab Res., doi:10.1155/2012/716404.
[24]-Kim M., Bae J., Kim T., Park J., Ahn Y., (2012): "Role of transcription factor modifications in the pathogenesis of insulin resistance". Exp Diab Res., doi:10.1155/2012/716425.
[25]-Younossi M., McCullough J., Ong P.,Barnes S., et al., (2004): "Obesity and non-alcoholic fatty liver disease in chronic hepatitis". C J Cli Gastro., 38: 705-09.
[26]-Nail A., Gadour M., Kair M., Salma M., et al., (2006): "Fatty liver disease in Sudan is not alcohol related". Sud J M S., 1(2): 97-102.
[27]-Hatziagelaki E., Karageorgopoulos D., Chounta A., Tsiavou A., et al., (2012): "Predictors of impaired glucose regulation in patients with Non-alcoholic fatty liver disease". Exp Diab Res., doi:10.1155/2012/351974.
[28]-Jick S., Stender M., Myers M., (1999): "Frequency of liver disease in type 2 diabetic patients treated with oral anti diabetic agents". Diab Care, 22: 2067-2071.
[29]-Al-Habbo D., Khalaf Y., Alkhiat N., Habash A.,(2009): "The prevalence of fatty liver disease among diabetics in Mosoul". Ann CollMed., 35(1): 50-57.
[30]-El-Sayed S., El-Folly R., Ahmed A.,(2014): "Assessment of the co-incidence between nonalcoholic fatty liver disease and carotid atherosclerosis". J Egy Soc Par., 44(1): 187-195.
[31]-IDF:http://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html.
[32]-Khov N., Sharma A., Riley T., (2014): "Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease". World J Gastr., 20(22): 6821-25.
[33]-Neuschwander-Tetri B., (2017): "Non-alcoholic fatty liver disease" . B M C Med., 15: 1-6.
[34]-Jorgensen M., Roberta N., (2003): "Non-alcoholic fatty liver disease". Gastr Nur., 26: 150-154.
[35]-Niaz A., Ali Z., NayyarS., Fatima N., (2011): "Prevalence of NAFLD in healthy and young male individuals". Int Sch Res Net Gastr., doi:10.5402/2011/363546.
[36]-Javadi L., Ghavami M., Khoshbaten M., Safaiyan A., et al., (2017): " The effect of probiotic and / or prebiotic on liver function tests in patients with Nonalcoholic fatty liver disease; A double blind randomized clinical trial". I Red Cre Med J., 19(4): e46017.
[37]-Abangah G., Yousefi A., Asadollahi R., Veisani Y., et al., (2014): " Correlation of body mass index and serum parameters with ultrasonographic grade of fatty change in Non-alcoholic fatty liver disease". I Red Cre Med J., 16(1): e12669.
[38]-Raffeey M., Mortazavi F., Mogaddasi N., Robabeh G., et al., (2009): "Fatty liver in children". Ther Cli Risk Manag., 5(2): 371-374.
[39]-Akbar D., Kawther A., (2006): "Non-alcoholic fatty liver disease and metabolic syndrome". Med Sci Mon., 12(1): 23-26.
Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
In a brief statement, the rights relate to the publication and distribution of research published in the journal of the University of Sebha where authors who have published their articles in the journal of the university of Sebha should how they can use or distribute their articles. They reserve all their rights to the published works, such as (but not limited to) the following rights:
- Copyright and other property rights related to the article, such as patent rights.
- Research published in the journal of the University of Sebha and used in its future works, including lectures and books, the right to reproduce articles for their own purposes, and the right to self-archive their articles.
- The right to enter a separate article, or for a non-exclusive distribution of their article with an acknowledgment of its initial publication in the journal of Sebha University.
Privacy Statement The names and e-mail addresses entered on the Sabha University Journal site will be used for the aforementioned purposes only and for which they were used.